News
Cardio Diagnostics Holdings Inc Announces Expansion of IP Portfolio with Notice of Allowance of Patent Application
Thursday, March 9, 2023
Cardio Diagnostics Holdings, Inc., a pioneering precision cardiovascular medicine company founded by UI faculty Dr. Robert Philibert and UI graduate Dr. Meesha Dogan, today announced that China’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Chinese Patent Application No. 201780049286.4.
Iowa Lichtenberger Engineering Library receives Patent & Trademark Resource Center designation
Monday, January 30, 2023
The University of Iowa Lichtenberger Engineering Library is now part of a select group of higher education institutions across the country—and only one in Iowa—to be designated a Patent and Trademark Resource Center (PTRC) by the U.S. Patent and Trademark Office (USPTO).
CJ partners with Emmyon to develop ingredients preventing muscle atrophy
Thursday, December 22, 2022
South Korean food giant CJ CheilJedang Corp. announced on Tuesday that it has signed a license contract with Emmyon, an University of Iowa biotechnology startup, to utilize Emmyon's various patents regarding ursolic acid, at its headquarters in Jung-gu, Seoul.
Cardio Diagnostics Holdings, Inc. to List on Nasdaq Following Successful Business Combination with Mana Capital Acquisition Corp.
Thursday, October 27, 2022
Cardio Diagnostics Holdings, Inc., a pioneering precision cardiovascular medicine company founded by UI faculty Dr. Robert Philibert and UI graduate Dr. Meesha Dogan, today announced the completion of its business combination with Mana Capital Acquisition Corp., a publicly traded special purpose acquisition company.
Lilly to Acquire Akouos for Up to $610M, Expanding Gene Therapy Focus
Friday, October 21, 2022
Eli Lilly has agreed to acquire Akouos for up to $610 million, in a deal intended to expand the buyer’s presence in gene therapy with a focus on treating inner ear disorders. Akouos, which has licensed key technology from the University of Iowa, develops targeted adeno-associated viral (AAV) vector-based gene therapies for conditions that include sensorineural hearing loss, integrating expertise in otology and inner ear drug delivery, as well as gene therapy.
Explore the tech transfer process through live virtual courses with commercialization experts
Wednesday, October 5, 2022
The University of Iowa Research Foundation (UIRF) will host a series of online courses about how to move technology from the university to the marketplace for all University of Iowa faculty, staff, postdocs, and graduate students.
Villafana-led Medtech Firm Medical 21 Secures $20M in Financing
Friday, September 30, 2022
Medical device company Medical 21, founded on technology developed at the UI by Prof. Suresh Raghavan, announced that it has landed a $20 million commitment from an individual investor.
Viewpoint Molecular Targeting Announces Transformational Merger
Thursday, September 29, 2022
Viewpoint Molecular Targeting, UI start-up company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that it has entered into a definitive agreement to merge with Isoray, Inc (NYSE AMERICAN:ISR), a medical technology company and innovator in seed brachytherapy.
Cardio Diagnostics Announces Issuance of U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
Friday, September 23, 2022
Cardio Diagnostics, a pioneering precision cardiovascular testing company founded by UI faculty Dr. Robert Philibert and UI graduate Dr. Meesha Dogan, announced that the U.S. Patent and Trademark Office has issued to the University of Iowa Research Foundation ("UIRF") U.S. Patent No. 11,414,704 titled COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE, which is exclusively licensed to the Company from UIRF.
Digital Diagnostics Closes $75 million Series B Funding Round led by KKR
Tuesday, August 23, 2022
Digital Diagnostics, a leading artificial intelligence diagnostic health care technology company founded by UI faculty Dr. Michael Abramoff, today announced that it has successfully closed a $75 million Series B funding round.
Pagination